Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29683191 | 0.94 | BRAF (0.73) | BRAFMAP3K20 | |
| SCHEMBL21046902 | 0.94 | BRAF (0.73) | BRAFMAP3K20 | |
| Trifluoroacetic Acid SCHEMBL29682997 | 0.93 | BRAF (0.72) | BRAFMAP3K20 | |
| SCHEMBL21046955 | 0.92 | BRAF (0.83) | BRAFMAP3K20 | |
| SCHEMBL21046746 | 0.90 | BRAF (0.85) | BRAFMAP3K20 | |
| SCHEMBL21046722 | 0.90 | BRAF (0.81) | BRAFMAP3K20 | |
| SCHEMBL21046779 | 0.90 | BRAF (0.81) | BRAFMAP3K20 | |
| SCHEMBL21046852 | 0.89 | MAP3K20 (0.84) | BRAFMAP3K20 | |
| SCHEMBL29683373 | 0.89 | MAP3K20 (0.84) | BRAFMAP3K20 | |
| SCHEMBL21047158 | 0.88 | BRAF (1.00) | BRAFMAP3K20 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021222147-A1 | HETEROCYCLIC GCN2 MODULATORS | HIBERCELL, INC. (US) | 2021-11-04 | — | — | WO | claimed |
| EP-3498693-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2024-10-30 | — | — | EP | disclosed |
| CN-109790122-B | Heterocyclic compounds | 武田药品工业株式会社 | 2022-06-24 | — | — | CN | disclosed |
| WO-2021222147-A1 | HETEROCYCLIC GCN2 MODULATORS | HIBERCELL, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| US-10696651-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-06-30 | — | — | US | disclosed |
| US-10696651-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-06-30 | — | — | US | disclosed |
| EP-3498693-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2019-06-19 | — | — | EP | disclosed |
| US-20190169166-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-06-06 | — | — | US | disclosed |
| US-20190169166-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696651-B2 | Heterocyclic compound | EIF2AK4, GCN1, GTF2I | BRAF 1618/4885MAP3K20 814/4885 |
| US-20190169166-A1 | HETEROCYCLIC COMPOUND | EIF2AK4, GCN1, GTF2I | BRAF 1618/4885MAP3K20 814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.